Zoetis Beats Q2 Estimates On Strong U.S. Pet-Care Sales

Shares of animal-health giant Zoetis (ZTS) rose to a 13-month high in early trading Wednesday after the company beat Q2 estimates and modestly raised its guidance.

Earnings grew 14% over the year-earlier quarter and beat analysts' consensus by 11%, while sales rose 3% and topped estimates by 3%. Zoetis' U.S. pet-care business did especially well, with 17% growth, helped by the canine itching treatment Apoquel, as well as the newly approved oral flea killer Simparica. International growth...

What feeling does this article give you?

#hashtags to follow:

Zoetis [+]    ZTS [+]    Apoquel [+]    Simparica [+]   

More #news: